Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exebacase (Primary)
  • Indications Bacteraemia; Bacterial endocarditis; Skin and soft tissue infections; Staphylococcal infections
  • Focus Adverse reactions; First in man
  • Sponsors ContraFect

    • Most Recent Events

    • 15 Mar 2018 According to ContraFect media release, results from the study presented at the American Society for Microbiology Microbe 2017 conference.
    • 01 Jun 2017 New analyses of clinical data from this trial will be presented at the American Society for Microbiology (ASM) Microbe 2017 conference according to a ContraFect Corporation media release.
    • 25 Apr 2017 Results of long term immunology follow up, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top